QR Code

Splicing correction by peptide-conjugated morpholinos as a novel treatment for late-onset Pompe disease

Late-onset Pompe disease (LOPD) is overwhelmingly caused by a single mutation that disrupts splicing of acid-alpha glucosidase (GAA) and results in the accumulation of lysosomal glycogen in muscle cells leading to progressive muscle weakness in patients. Current therapeutics for LOPD do not meet the...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Ryan A. Oliver, Meghan E. Ahern, Perla G. Castaneda, Tushare Jinadasa, Anirban Bardhan, Kathy Y. Morgan, Kristin Ha, Kailash Adhikari, Nino Jungels, Noa Liberman, Anindita Mitra, Christopher D. Greer, Alec M. Wright, Emily G. Thompson, Stephanie Garcia, Elena Copson, Senkara Allu, Xuyu Tan, Alex J. Callahan, Bao Zhong Cai, Vincent Guerlavais, Kevin J. Kim, Annika B. Malmberg
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Elsevier 2025-06-01
Rangatū:Molecular Therapy: Nucleic Acids
Ngā marau:
MT: Oligonucleotides: Therapies and Applications
late-onset Pompe disease
lysosomal storage disease
oligonucleotide therapeutics
RNA medicines
splice switching antisense oligonucleotide
Urunga tuihono:http://www.sciencedirect.com/science/article/pii/S2162253125000782
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite